水飞蓟宾葡甲胺片治疗非酒精性脂肪性肝炎

目的:探讨水飞蓟宾葡甲胺片对大鼠非酒精性脂肪性肝炎的治疗作用及机制。方法:雄性SD大鼠39只,正常喂养1周后随机分为正常对照组(n=9)和造模组(n=30),正常对照组予标准饮食,造模组予高脂饮食。11周末验证造模成功后,将模型动物再分为5组:高脂组(Z组,予高脂饮食及生理盐水ig)、正常饮食组(Y组,予标准饮食及生理盐水ig)、水飞蓟宾葡甲胺片高(A组)、中(B组)及低剂量(C组),剂量分别为100,50,25 mg.kg-1,ig及标准饮食。均连续4周。16周末处死大鼠,检测肝指数、体脂比、血清丙氨酸转移酶(ALT)、天冬氨酸氨基转移酶(AST)、甘油三酯(TC)、总胆固醇(TG)、低密度脂蛋白(LDLC)、血糖(GLU)、超氧化物歧化酶(SOD)、丙二醛(MDA),并行肝组织病理检查及肝匀浆TC,TG,LDLC和MDA测定。结果:第11周末造模组大鼠肝指数、血清AST,TC,TG,LDLC,GLU,MDA水平及肝匀浆TC,TG,MDA水平明显增高,与正常对照组比(P0.05);治疗组肝组织出现明显脂肪变性、炎症及纤维化(P0.05)。试验结束时,A组及B组体脂降低;A组血清AST,TC水平明显降低,B组血清MDA水平明显降低(P0.05);B组肝匀浆TC,LDLC水平明显降低。各治疗组较Y组及Z组肝组织的脂肪变程度、炎症程度和纤维化程度均明显减轻(P0.05)。结论:水飞蓟宾葡甲胺片可有效治疗大鼠非酒精性脂肪性肝炎。

Effect of Silybin meglumine Tablets on Treatment of Nonalcoholic Steatohepatitis in Rats

Objective :To investigate the protective effect and mechanism of Silybin meglumine on rat model of nonalcoholic steatohepatitis (NASH). Method :After one week of a standard diet 39 male SD rats were randomly divided into the normal control group (n=9) and the experimental group (n=30). The normal control group rats were fed with a standard diet, while those of the experimental group with a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly subdivided into five groups: Group Z (n=5) with a high-fat diet and gastric with saline, Group Y (n=5) with a standard diet and gastric with saline, Group A (n=5), Group B (n=5) and Group C (n=5) with a standard diet and gastrically infused with the S. meglumine solution of high-dosage (100 mg ·kg-1 ·d^-1), middle-dosage (50 mg ·kg^-1 ·d^-1) and low-dosage (25 mg ·kg^-1 ·d^-1), respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum alanine aminotransferase (ALT),aspartic acid aminotransferase (AST), triglyceride (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDLC), glucose (GLU), superoxide dismutase (SOD) and malondialdehyde (MDA). Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDLC and MDA levels. Result :At the end of the week 11 there was a significant difference in the hepatic index, the levels of serum AST, TC, TG, LDLC, GLU, SOD, MDA, the levels of liver tissue TC, TG, MDA, and the histological changes of liver injury between the experimental group and the normal control group (P<0.05). At the end of the week 16, the visceral adiposity ratio, serum AST and TC levels were higher in Group Y than that in Group A (P<0.05). Significant decreases were found in the visceral adiposity ratio, serum MDA levels, and liver tissue TC and LDLC levels in Group B compared to Group Y (P<0.05). A significant reduction was observed in Group A, B and C in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z (P<0.05). Conclusion :S. meglumine seem to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.